Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for ADHD Symptoms in Children and Adolescents with ASD
NCT00380692Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Oct 2006; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00380692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380692.